ARTICLE

Ring-deactivated hydroxyalkylpyrrole-based inhibitors of α -chymotrypsin: synthesis and mechanism of action

Derek C. Martyn, Andrea J. Vernall, Bruce M. Clark and Andrew D. Abell* Department of Chemistry, University of Canterbury, Christchurch, New Zealand. *E-mail: a.abell@chem.canterbury.ac.nz; Fax: 64-3-3642110; Tel: 64-3-3642818*


Received 5th March 2003, Accepted 12th May 2003 First published as an Advance Article on the web 27th May 2003



¹³C NMR and mass spectrometry studies have been used to demonstrate that the inhibition of α -chymotrypsin by *N*-sulfonylhydroxymethylpyrrole inhibitors (**10**) is non-covalent. Hydroxyalkylpyrroles in which an electronwithdrawing group (acyl substituent) is introduced at the alternative C2 position have been synthesised and also shown to inactivate α -chymotrypsin. SAR studies on this class suggests that the incorporation of phenylalanine at C2 is favoured, however, there is little gain in introducing a hydrophobic substituent at C5.

Introduction

In previous work¹ we reported a series of hydroxymethylpyrroles substituted on nitrogen with an electron withdrawing group (EWG) (see 1 in Scheme 1) as a new class of inhibitor of α -chymotrypsin, a representative example of a class of enzyme known as serine proteases.² These compounds were postulated to act as mechanism-based inhibitors based upon model hydrolysis studies³ and extensive chemical precedence.^{4,5} In particular, hydrolytic removal of the EWG from 1, in a process that mimics normal protease action on a substrate peptide, allows for the liberation of a highly electrophilic azafulvene (3) that is free to react with an available nucleophile (Scheme 1).³ We proposed that this process could result in enzyme inactivation if it occurred in the vicinity of a catalytic group in the enzyme active site.¹



Peptidomimetics 1 can be considered to be chemically stable analogues of a dipeptide substrate of α -chymotrypsin where the EWG mimics an amino acid on the *N*-terminus of the substrate scissile bond as depicted in 5, Fig. 1. In support of this notion we found ¹ that the best inhibitors of type 1 contained a hydrophobic EWG that mimics the aromatic P₁ group (see Fig. 1) † of a natural substrate of α -chymotrypsin, *i.e.* the point of natural cleavage of a peptide by α -chymotrypsin.⁶ We now report results of ¹³C NMR and mass spectrometric studies, using α -chymotrypsin and labelled inhibitor, that suggest that the mechanism of inhibition is in fact non-covalent in nature. We also report a new but related series of C2-acylated hydroxy-

[†] Note the use of Schechter–Berger nomenclature²² – the residues on the *N*-terminal side of the peptide bond that is cleaved are denoted (in order) P1–Pn, and those on the *C*-terminus are denoted P_1 – P_n . In turn, the corresponding subsites on the enzyme are denoted S_n – S_n'





Fig. 1 Schematic representation of two conformations of a natural substrate (middle) bound to the active site of α -chymotrypsin, and how these might correlate with the proposed *N*-acylhydroxymethylpyrrole **5** (top) and the *C*2-acylhydroxyalkylpyrrole **6** (bottom) inhibitors. The point of cleavage of the natural substrate is indicated by the bold arrow. Note the use of Schechter–Berger nomenclature. †

alkylpyrroles extended in the C-direction with an amino acid or dipeptide that also inhibit α -chymotrypsin by a non-covalent mechanism. These compounds have the EWG at C2 and as such mimic an alternative conformation of a natural substrate (see Fig. 1).

Results and discussion

We chose to use *N*-phenylsulfonylpyrrole **10a** (see Scheme 2) for the mechanistic studies since it is the most potent inhibitor of this type identified to date and also because it is readily available.¹ Initial ¹H NMR studies on **10a**, whereby it was incubated in CDCl₃ at room temperature for 7 days without degradation, illustrated that this compound is relatively stable and hence suitable for mechanistic studies. In addition, we have demonstrated that an *N*-sulfonyl group, of the type found in **10a**, is the strongest ring-deactivating group of those studied, and as such it is the best at suppressing azafulvene formation.⁵

In the first series of experiments we decided to incorporate a ¹³C-label into **10a** as a marker for monitoring changes to the electronic environment of the hydroxymethyl carbon on exposure to α -chymotrypsin. The target ¹³C labelled compound



Scheme 2 Reagents and conditions: (i) POCl₃, ¹³C-DMF, 1,2-DCE, reflux, 15 min, then $CH_3CO_2Na\cdot 3H_2O_{(aq)}$, reflux, 15 min (59%); (ii) PhSO₂Cl, 30% NaOH_(aq), Bu₄NI, CH₂Cl₂, rt, 30 h (91%); (iii) Zn(BH₄)₂, Et₂O, 0 °C, 30 min (90%).


10b was prepared using the method previously reported for **10a**¹ (Scheme 2) and a modification reported by Hinz *et al.*⁷ In particular, pyrrole was formylated with ${}^{13}C-N,N$ -dimethyl-formamide under Vilismeier–Haack conditions⁸ to give 8. This was reacted with phenylsulfonyl chloride under phase transfer catalysis⁷ to give 9, which was subsequently reduced with zinc borohydride⁵ to give the desired labelled derivative **10b**.

An analysis of the ¹³C NMR spectrum of a sample of **10b** incubated with α -chymotrypsin, using conditions previously reported for a different class of inhibitor,⁹ revealed an enriched resonance at 56 ppm, the same chemical shift as was observed for **10b** in the absence of enzyme. \ddagger In addition, an electrospray mass spectrum of the product from the incubation of **10a** with α -chymotrypsin revealed signals at 25,236 g mol⁻¹ (corresponding to the native enzyme), and 25,473 g mol⁻¹, a difference of 237 g mol⁻¹ which corresponds to the molecular mass of intact **10a**. These results strongly suggest that inhibitors **10** are not covalently attached to α -chymotrypsin as previously postulated.¹

We next decided to investigate the effect of introducing an EWG at the alternative C2-position of a hydroxymethylpyrrole (see general structure **6** in Fig. 1). Unlike structures of type **1** and **5**, these derivatives do not have the EWG directly attached to the pyrrole nitrogen and as such they mimic an extended conformation of a peptide backbone as depicted in Fig. 1. We reasoned that, while a C2-acyl group as in **6** would still deactivate the pyrrole, it would do so to a lesser extent. As such azafulvene formation would be more favoured, which should in turn promote inactivation of α -chymotrypsin by a covalent mechanism. It is also important to note that compounds of type **6** allow for chain extension in the C-direction and also the incorporation of a range of groups in the P₁ position. A series of such compounds was prepared and assayed against α -chymotrypsin.

Scheme 3 details the synthesis of compounds of type 6 that bear a hydrogen at R¹ (P₁ group as defined for a substrate in Fig. 1). Three derivatives (14a–c) were prepared to investigate the effect of the nature of the appended amino acid on inhibitory potency. Phenylalanine was used (14a) as it is known that the S₂' subsite of α -chymotrypsin preferentially accommodates large, hydrophobic moieties of this type (see Fig. 1).^{10,11} Leucine and proline were chosen in order to test this hypothesis in our series and to gain some possible insight into the mode of enzyme binding. The synthesis of compounds 14 began with the formylation of the pyrrole ester 11¹² under Vilismeier– Haack conditions¹³ to give 12a, which would eventually give rise to the hydroxymethyl side chain of 14a–c. Hydrolysis of the ester of 12a with potassium hydroxide gave the key intermedi-


 \ddagger A difference spectrum was determined by subtracting the ¹³C NMR spectrum of **10a** (unlabelled) with α -chymotrypsin from that of **10b** (labelled) with α -chymotrypsin according to the published method.⁹



Scheme 3 Reagents and conditions: (i) $POCl_3$, DMF, 1,2-DCE, reflux, 15 min, then $CH_3CO_2Na \cdot 3H_2O$, reflux, 15 min (61%); (ii) KOH, H_2O , 40–50 °C, 2 h (60%); (iii) EDCI, HOBT, DIEA, CH_2Cl_2 , rt, 16 h and either L–PheOMe·HCl (13a, 71%), L–LeuOMe·HCl (13b, 61%), or L–ProOMe·HCl (13c, 74%); (vi) Zn(BH_4)₂, ether, 0 °C, 1 h (14a, 57%), (14b, 42%), (14c, 24%); (v) LiBH₄, ether, -78 °C, 1 h (14b, 66%).

ate **12b** in 60% yield.¹⁴ The free acid of **12b** was then separately coupled with L-phenylalanine methyl ester hydrochloride, L-leucine methyl ester hydrochloride and L-proline methyl ester hydrochloride, using standard EDCI conditions,¹⁵ to give **13a**,**b** and **c** respectively. Reduction of the 5-formyl moiety of **13a–c** with zinc borohydride gave the desired dipeptide analogues **14a–c** in reasonable yields. The use of lithium borohydride, instead of zinc borohydride, for the reduction of **13b** gave an improvement in yield from 42% to 66%.

Next we prepared compounds **18a** (Scheme 4) in which R¹ (see general structure **6**, Fig. 1) more closely correlates to the known specificity of the P₁ group of a substrate of α -chymotrypsin (see Fig. 1). We also prepared compounds **18b** in which R¹ (Me) is of intermediary size, *cf*. H and (CH₂)₂Ph of **14a**-c and **18a**, respectively. To this end, the pyrrole **11** was acylated with either hydrocinnamoyl chloride or acetyl chloride ¹⁶ to give **15a** and **15b**, respectively. Hydrolysis of the ethyl esters of **15a** and **15b** with potassium hydroxide gave the acids **16a** and **16b** which were then separately coupled with L-phenylalanine methyl ester hydrochloride (as for **12b**) to give **17a** and **17b**. A final reduction of the 5-keto group of **17a** and **17b** with zinc




Scheme 4 Reagents and conditions: (i) $ZnCl_2$, 1,2-DCE, 50 °C, 1 h and Ph(CH₂)₂COCl (15a, 35%) or AcCl (15b, 37%); (ii) KOH, 2 : 1 H₂O-THF, 40–50 °C, 2 h (16a, 86%), (16b, 93%); (iii) L–PheOMe·HCl, EDCI, HOBT, DIEA, CH₂Cl₂, rt, 16 h (17a, 70%), (17b, 91%); (iv) $Zn(BH_4)_2$, ether, 0 °C, 1 h (18a, 21%), (18c); (v) LiBH₄, ether, -78 °C, 1 h, then rt, 1 h (18b, 46%).

Table 1 Inhibition of α-chymotrypsin by 14a-c, 18a and 22


$HO _{\substack{X^{1} \\ R^{1}}} N \underset{H}{\overset{N}{\overset{N}{}}} \bigcup_{O} X$						
	R ¹	X	% Inhibition (µg mL ⁻¹)			
Compound			1250	125	12.5	
14a	Н	NH–L–PheOMe	75	35	45	
14b	Н	NH–L–LeuOMe	10	5	20 ^{<i>a</i>}	
14c	Н	N-L-ProOMe	45	25	5	
18a	Ph(CH ₂),	NH–L–PheOMe	75	35	15	
22	Н	NH–L–Phe–L–LeuOMe	100	20	15	

borohydride gave the extended peptide analogues 18a and 18b as 1 : 1 mixtures of epimers by ¹H NMR. An over reduction was observed in the case of 17a, with the production of an almost equal amount of by-product 18c. Compound 18b proved to be somewhat unstable and its purification problematic. An alternative preparation of 18b was also investigated as outlined in Scheme 5. Here, the formyl group of pyrrole 12a was reacted with methyllithium to give 19a. Subsequent ethyl ester hydrolysis with sodium hydroxide gave 19b in low yield, which was then coupled to L-phenylalanine methyl ester hydrochloride to give 18b, which again proved difficult to purify and was ultimately unstable.



Scheme 5 Reagents and conditions: (i) MeLi, THF, -23 °C, 5 h (95%); (ii) NaOH, 1 : 1 THF-H₂O, 40–50 °C, 24 h (17%); (iii) L–PheOMe•HCl, EDCI, HOBT, DIEA, CH₂Cl₂, rt, 16 h (54%).

Finally, we prepared an extended tetrapeptide analogue **22** based upon the simple hydroxymethylpyrrole scaffold of compounds **14a–c**. We chose to extend the peptide in the C-direction using L-phenylalanyl-L-leucine since this sequence is known to favour binding to α -chymotrypsin.^{17,18} This sequence also allows for a direct comparison with **14a**, which simply has L-phenylalanine attached. The required starting dipeptide ester **20b** was prepared from commercially available L-phenylalanyl-L-leucine hydrate **20a** on treatment with diazomethane (Scheme 6). This dipeptide methyl ester was then coupled to **12b** in the



Scheme 6 Reagents and conditions: (i) CH_2N_2 , THF, rt, 15 h; (ii) 12b, BOP, DIEA, CH_2Cl_2 , rt, 16 h (52% yield over two steps); (iii) LiBH₄, THF, -78 °C, 1 h, then rt, 1 h (66%).

presence of BOP¹⁹ to give 21 in 52% yield over two steps. Reduction with lithium borohydride then gave 22.

The peptidomimetics 14a-c, 18a (as a mixture of diastereomers) and 22 were assayed against α -chymotrypsin at three concentrations using a simple screening assay as described previously¹ and the results are presented in Table 1 (compound 18b proved too unstable to assay). From these results it is apparent that there is not a significant difference in the inhibitor potency of compounds 14a and 18a, compounds that differ solely in the nature of R^1 (see 6 in Fig. 1). We had postulated that the hydrophobic group of 18a might be favoured (see earlier for a discussion). However, it is important to remember that 18a was assayed as a mixture of diastereomers and as such one isomer may be more active than the other. A comparison of the inhibitory assay results obtained for the four compounds (14a-c and 22) that contain a hydroxymethylpyrrole moiety suggest a slight preference for a phenylalanine in the appended X group. The tetrapeptide analogue 22 proved the most potent and an IC₅₀ value of 108 µM was determined for this compound. LCMS studies were also performed on α-chymotrypsin incubated with 14a at 37 °C for 3 hours in 50 mM Tris-HCl. As for 10, there was no evidence of covalent attachment of the inhibitor to the enzyme. Finally, it should be noted that 2-acylhydroxyalkylpyrroles of general structure 6 (see 14a-c, 18a and 22 in Table 1) are similarly active to the compounds in which the EWG is substituted on nitrogen (see 1 and 5).¹

Conclusion

N-Substituted hydroxymethylpyrroles of general type **1** are known to inhibit α -chymotrypsin. In this paper we have used a combination of mass spectrometry and ¹³C NMR experiments to show that compounds of type **1** (specifically **10**) do not form a covalent attachment to the enzyme. A modified series of compounds was then prepared in which a peptidic side chain is attached to the pyrrole nucleus at C2. Assay results for this series reveal that, while compounds with a phenylalanine residue as part of the C2 side chain (X in Table 1) are the most potent inhibitors of α -chymotrypsin, there is little gain in introducing a more hydrophobic substituent at C5 (R¹ in Table 1). The IC₅₀ value for the most potent compound (**22**) in this new series of inhibitor of α -chymotrypsin was determined to be 108 μ M. Again it appears that these compounds inhibit α -chymotrypsin *via* a non-covalent mechanism.

Experimental

All melting points were obtained on an Electrothermal apparatus and are uncorrected. Proton NMR spectra were obtained on a Varian Inova spectrometer, operating at 500 MHz. Carbon NMR were obtained on a Varian Unity 300 spectrometer, operating at 75 MHz. IR spectra were obtained using a Shimadzu 8201PC series FTIR, either in CHCl₃ (solution phase), or in

solid KBr (diffuse reflectance). Molecular masses of products were detected on a Kratos MS80 RFA mass spectrometer. Inhibitor-enzyme samples were analysed initially by electrospray ionisation mass spectrometry (ESI) using a Micromass LCT mass spectrometer scanning at 100-2500 atomic mass units (scans every 0.9 s, 0.1 s delay). The source was at 80 °C (ESI probe = $150 \degree$ C, nebuliser = $190 \text{ L} \text{ h}^{-1}$, desolvation = 350 L h^{-1}). Liquid chromatography mass spectrometry (LCMS) was carried out on a Waters 2790 LC coupled to the Micromass LCT spectrometer using a Waters 996 PDA Zorbax C3 column (150 mm \times 2 mm \times 5 µm, flow 0.2 cm³ min⁻¹). The mobile phase consisted of a gradient of 100% [water-0.5% formic acid] to 40% [water-0.5% formic acid]-60% acetonitrile over 80 min, then to 100% acetonitrile over 5 min, held at 100% acetonitrile for 10 min, then back to 100% [water-0.5% formic acid] over 5 min. Data was processed with Maxent[®] software. a-Chymotrypsin assays were carried out in microtitre plates (twelve 1×8 well Titertek® microtitre strips) and read in a BMG Labtechnologies Fluostar Galaxy 96-well plate reader. Compounds 11,¹² 12a¹³ and 12b¹⁴ were prepared by literature methods. Flash chromatography was performed using 230-400 mesh Merck Silica Gel 60 under positive pressure. All solvents were distilled prior to use using literature procedures.²⁰

a-Chymotrypsin inhibition experiments

Assay²¹. Solutions of 14a-c, 18a and 22 were made to 1250 μg cm³, 125 μg cm³ and 12.5 μg cm³ in methanol. Tris-HCl (50 µL of a 0.4 M solution in water, pH 7.6), distilled water (50 µL), inhibitor solution (50 μ L) and α -chymotrypsin (50 μ L, Sigma ex-bovine pancreas, 9 units cm³ in 50 mM Tris-HCl, pH 7.6) were added to each well of the microtitre plate. Incubation at 37 °C for 30 min was followed by the addition of N-succinyl-Lphenylalanine-4-nitroanilide (100 µL, 1 mg per cm³ solution in 50 mM Tris-HCl buffer, pH 7.6). The absorbance was read at 405 nm at hourly intervals until the maximum measured absorbance exceeded 1.00 absorbance units. Each inhibitor concentration was assayed in triplicate and average absorbances were used to calculate the percentage (%) inhibition. Sample blanks to determine the absorbance for each inhibitor concentration in the absence of enzyme (i.e. no substrate turnover) were run concurrently, in which Tris-HCl (50 µL of a 50 mM solution in water, pH 7.6), replaced α -chymotrypsin. Maximum substrate turnover was determined by averaging the absorbance readings from six wells in which methanol (50 μ L) replaced the inhibitor solution. All percentage (%) inhibition figures reported are rounded to the nearest 5%. The IC_{50} for 22 was determined using the same general method except that solutions of 22 were made to 12.0 mM, 3.01 mM, 0.75 mM, 0.19 mM, 47.0 µM, 11.8 µM, 2.94 µM and 0.73 µM. Precipitation occurred in all wells where 22 was present at a concentration of 12.0 mM, so no inhibition value could be calculated at this concentration. Each sample was assayed in triplicate. The IC_{50} value was calculated by fitting the inhibitor concentrationpercent inhibition data into Microsoft Excel.

¹³C NMR and LCMS. Stock solution A was made up by dissolving **10b** (2 mg) in DMSO (225 μL), followed by addition of D₂O (2.775 cm³) to give a final concentration of 2.8 mM. Stock solution B was made up by dissolving α-chymotrypsin (71 mg, Sigma ex-bovine pancreas) in DMSO (75 μL) followed by addition of D₂O (925 μL) to also give a concentration of 2.8 mM. Stock solution C was made up as for A using **10a** in place of **10b**. Solution A (300 μL) and separate mixtures of A and B (300 μL, 1 : 1) and B and C (300 μL, 1 : 1) were then left at room temperature for one hour, shaking occasionally. The samples were transferred to NMR tubes and the ¹³C NMR spectra were determined and analysed as described.⁹ LCMS experiments on enzyme inhibitor complexes were carried out on **10a**, **10b** and **14a** in solution in Tris–HCl buffer.

General procedure A: peptide couplings using EDCI

To a stirred solution (~0.1 M) of the pyrrole carboxylic acid (1 equiv.) and the L-amino acid ester hydrochloride (1.1 equiv.) in dry dichloromethane (~8 cm³), at rt under an inert atmosphere, were added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.3 equiv.) and 1-hydroxybenzotriazole hydrate (1.5 equiv.). *N*,*N*-Diisopropylethylamine (1.1 equiv.) was added, and the reaction mixture was stirred at rt for 16 h. The solution was then diluted with dichloromethane (10 cm³), washed with 3 M aqueous hydrochloric acid (2×10 cm³), water (2×10 cm³), dried (MgSO₄) and the solvent was removed by evaporation under reduced pressure. The resultant material was purified by flash chromatography on silica. See individual experiments for details.

Modification to general procedure A

The reaction was performed in the manner as described in general procedure A, except that the combined aqueous washings were back-extracted with dichloromethane $(2 \times 10 \text{ cm}^3)$, and the combined organic fractions were then dried (MgSO₄). The solvent was removed by evaporation under reduced pressure, and the resultant material was purified by flash chromatography on silica. See individual experiments for details.

General procedure B: zinc borohydride reductions

A stirred solution (~0.1 M) of the pyrrole (1 equiv.), dissolved in dry ether under an inert atmosphere, was cooled to 0 °C. Zinc borohydride (2.2 equiv. of a 0.14 M solution in ether) was added, and the resultant solution was stirred at 0 °C for 1 h. Water (1 cm³), and then 10% aqueous acetic acid (1 cm³), were carefully added to quench the reaction. The separated aqueous phase was extracted with dichloromethane (2 × 10 cm³), and the combined organic phases were washed with water (2 × 10 cm³), saturated aqueous brine (10 cm³), dried (MgSO₄) and the solvent was removed by evaporation under reduced pressure. The resultant material was purified by flash chromatography on silica. See individual experiments for details.

[*FormyI*-¹³*C*]-1*H*-pyrrole-2-carboxaldehyde (8). Prepared from 7 (210 mg, 3.13 mmol) using phosphorous oxychloride (526 mg, 3.43 mmol) and *N*,*N*-dimethylformamide-*carbonyI*-¹³*C* (255 mg, 3.43 mmol) as described for unlabelled **8**⁸ (177 mg, 59%); $\delta_{\rm H}(500 \text{ MHz}; \text{ CDCl}_3; \text{ Me}_4\text{Si})$ 6.36 (1 H, m, pyrrole 4-H), 7.02 (1 H, m, pyrrole 3-H), 7.18 (1 H, m, pyrrole 5-H), 9.51 (1 H, m, *J* = 175.3 Hz, *CHO*), 10.39 (1 H, br s, *NH*); $\delta_{\rm C}(75 \text{ MHz}; \text{ CDCl}_3; \text{ Me}_4\text{Si})$ 111.3, 121.8, 126.9, 132.7, 179.4 (*C*HO enriched peak).

[*Formyl*-¹³*C*]-1-(phenylsulfonyl)pyrrole-2-carboxaldehyde (9). Prepared from 8 (110 mg, 1.14 mmol) as described for unlabelled 9⁷ (212 mg, 91%); $\delta_{\rm H}$ (500 MHz; CDCl₃; Me₄Si) 6.42 (1 H, t, *J* = 3.4 Hz, pyrrole 4-H), 7.16 (1 H, m, pyrrole 3-H), 7.54–7.64 (4 H, m, pyrrole 5-H and Ar*H*), 7.92 (2 H, m, Ar*H*), 9.95 (1 H, d, *J* = 182.6 Hz, C*H*O); $\delta_{\rm C}$ (75 MHz; CDCl₃; Me₄Si) 112.5, 124.8, 127.4, 129.5, 133.5, 134.5, 138.1, 178.7 (*C*HO enriched peak).

[*Methylene-*¹³*C*]-2-hydroxymethyl-1-(phenylsulfonyl)pyrrole (10b). Prepared from 9 (62 mg mg, 0.30 mmol) as described for 10a¹ (56 mg, 90%); $\delta_{\rm H}$ (500 MHz; CDCl₃; Me₄Si) 2.78 (1 H, br s, OH), 4.60 (2 H, d, *J* = 145.0 Hz, CH₂OH), 6.24–6.27 (2 H, m, pyrrole 4-H and pyrrole 3-H), 7.27 (1 H, m, pyrrole 5-H), 7.50– 7.62 (3 H, m, ArH), 7.82 (2 H, m, ArH); $\delta_{\rm C}$ (75 MHz; CDCl₃; Me₄Si) 57.7 (CH₂OH enriched peak), 112.0, 115.4, 123.6, 126.6, 129.5, 134.0, 134.6, 139.0.

N-(5-Formyl-1*H*-pyrrole-2-carbonyl)-L-phenylalanine methyl ester (13a). The pyrrole acid $12b^{14}$ (100 mg, 0.72 mmol, 1 equiv.) was coupled with L-phenylalanine methyl ester hydro-

chloride (171 mg, 0.79 mmol, 1.1 equiv.) according to general procedure A. The resultant material was purified by flash chromatography on silica (ethyl acetate–petroleum ether, 2 : 1) to give **13a** (152 mg, 71%) as a cream solid; mp 48–51°; v_{max} (CHCl₃)/cm⁻¹ 1529.4, 1550.7, 1676.0, 1739.7, 3020.3, 3423.4; δ_{H} (500 MHz; CDCl₃; Me₄Si) 3.22 (2 H, m, CH₂Ph), 3.76 (3H, s, CO₂CH₃), 5.06 (1 H, m, NHCH), 6.51 (1 H, d, J = 7.3 Hz, NHCH), 6.61 (1 H, dd, J = 2.7, 4.2 Hz, pyrrole 3-H), 6.91 (1 H, dd, J = 2.7, 4.2 Hz, pyrrole 4-H), 7.10 (2 H, m, ArH), 7.27 (3 H, m, ArH), 9.61 (1 H, s, CHO), 10.11 (1 H, br s, pyrrole NH); ¹³C NMR (75 MHz; CDCl₃; Me₄Si) δ 38.0, 52.6, 53.2, 111.2, 120.0, 127.2, 128.6, 129.3, 131.2, 134.0, 135.5, 159.3, 171.9, 180.3; *m/z* (ES) 301.1188 (M⁺ + H) C₁₆H₁₇N₂O₄ requires 301.1188, 301 (100%).

N-(5-Formyl-1*H*-pyrrole-2-carbonyl)-L-leucine methyl ester (13b). The pyrrole acid $12b^{14}$ (100 mg, 0.72 mmol, 1 equiv.) was coupled with L-leucine methyl ester hydrochloride (144 mg, 0.79 mmol, 1.1 equiv.) according to general procedure A. The resultant material was purified by flash chromatography on silica (ethyl acetate-petroleum ether, 2:1) to give 13b (116 mg, 61%) as a cream solid; mp 139-142 °C; v_{max}(CHCl₃)/cm⁻ 1529.4, 1550.7, 1676.0, 1739.7, 2960.5, 3018.4, 3425.3; $\delta_{\rm H}(500$ MHz; CDCl₃; Me₄Si) 0.96 (6 H, m, CH(CH₃)₂), 1.61-1.77 (3 H, m, CH₂CH), 3.77 (3 H, s, CO₂CH₃), 4.83 (1 H, m, NHCH), 6.62 (1 H, d, J = 8.3 Hz, NHCH), 6.68 (1 H, d, J = 2.4 Hz, pyrrole 3-H), 6.93 (1 H, d, J = 2.9 Hz, pyrrole 4-H), 9.62 (1 H, s, CHO), 10.18 (1 H, br s, pyrrole NH); $\delta_{\rm C}$ (75 MHz; CDCl₃; Me₄Si) 21.9, 22.8, 24.9, 41.7, 50.9, 52.6, 111.0, 120.0, 131.2, 133.9, 159.6, 173.7, 180.2; *m/z* (EI) 266.1266 (M⁺. C₁₃H₁₈N₂O₄ requires 266.1267), 210 (30%), 207 (38), 138 (12), 123 (26), 122 (75), 86 (100), 66 (20) and 44 (14).

N-(5-Formyl-1H-pyrrole-2-carbonyl)-L-proline methyl ester (13c). The pyrrole acid 12b¹⁴ (100 mg, 0.72 mmol, 1 equiv.) was coupled with L-proline methyl ester hydrochloride (131 mg, 0.79 mmol, 1.1 equiv.) according to modified general procedure A. The resultant material was purified by flash chromatography on silica (ethyl acetate-petroleum ether, 2 : 1 then 4 : 1) to give 13c (133 mg, 74%) as a white solid; mp decomp. >40 °C (Found: C, 57.63; H, 5.73; N, 11.21. C₁₂H₁₄N₂O₄ requires C, 57.59; H, 5.64; N, 11.19%); v_{max}(CHCl₃)/cm⁻¹ 1544.9, 1616.2, 1672.2, 1745.5, 3419.6; $\delta_{\rm H}$ (500 MHz; CDCl₃; Me₄Si) 2.01–2.27 (4 H, m, NCH₂CH₂CH₂CH), 3.73 (3 H, s, CO₂CH₃), 3.86 (1 H, m, NCH_{2a}CH₂CH₂CH₂CH), 3.97 (1 H, m, NCH_{2b}CH₂CH₂CH₂CH), 4.70 (1 H, m, NCH), 6.69 (1 H, m, pyrrole 3-H), 6.92 (1 H, m, pyrrole 4-H), 9.63 (1 H, s, CHO), 10.38 (1 H, br s, pyrrole NH); δ_{c} (75 MHz; CDCl₃; Me₄Si) 25.3, 28.6 (NCH₂CH₂CH₂CH), 48.5 (NCH₂CH₂CH₂CH), 52.3 (CO₂CH₃), 60.2 (NCH), 113.2 (pyrrole 3-C), 119.3 (pyrrole 4-C), 130.7 (pyrrole 2-C), 133.3 (pyrrole 5-C), 159.5 (CONH), 172.3 (CO₂), 180.1 (CHO); m/z (EI) 250.0952 (M⁺. C₁₂H₁₄N₂O₄ requires 250.0954), 218 (14%), 191 (47), 122 (26), 94 (12) and 70 (100).

N-(5-Hydroxymethyl-1H-pyrrole-2-carbonyl)-L-phenylalanine methyl ester (14a). The pyrrole 13a (106 mg, 0.35 mmol, 1 equiv.) was reduced with zinc borohydride according to general procedure B. The resultant material was purified by flash chromatography on silica (ethyl acetate-petroleum ether, 4:1) to give 14a (61 mg, 57%) as a tan solid; mp 105–107 °C (Found: C, 63.42; H, 5.90; N, 9.38. C₁₆H₁₈N₂O₄ requires C, 63.57; H, 6.00; N, 9.27%); v_{max}(CHCl₃)/cm⁻¹ 1525.6, 1637.5, 1739.7, 3035.7, 3435.0; $\delta_{\rm H}(500~{\rm MHz};~{\rm CDCl_3};~{\rm Me_4Si})$ 2.97 (1 H, br s, CH₂OH), 3.20 (2 H, m, CH₂Ph), 3.74 (3 H, s, CO₂CH₃), 4.65 (2 H, s, CH₂OH), 5.00 (1 H, m, NHCH), 6.08 (1 H, t, J = 3.2 Hz, pyrrole 4-H), 6.37 (1 H, d, J = 7.8 Hz, NHCH), 6.47 (1 H, t, J = 3.2 Hz, pyrrole 3-H), 7.12 (2 H, d, J = 7.3 Hz, ArH),7.27 (3 H, m, ArH), 10.31 (1 H, br s, pyrrole NH); $\delta_{\rm C}$ (75 MHz; CDCl₃; Me₄Si) 37.9 (CH₂Ph), 52.4 (CO₂CH₃), 53.2 (NHCH), 57.2 (CH₂OH), 108.1 (pyrrole 4-C), 110.9 (pyrrole 3-C), 124.5 (pyrrole 2-C), 127.1, 128.5, 129.1, 135.7 (Ar*C*), 136.8 (pyrrole 5-H), 161.3 (*C*ONH), 172.4 (*C*O₂); m/z (EI) 302.1264 (M⁺. C₁₆H₁₈N₂O₄ requires 302.1267), 284 (11%), 162 (20), 140 (77), 124 (100), 122 (21), 120 (21), 108 (30), 107 (24), 106 (88), 91 (70) and 78 (38).

N-(5-Hydroxymethyl-1*H*-pyrrole-2-carbonyl)-L-leucine

methyl ester (14b). Method 1. The pyrrole 13b (116 mg, 0.44 mmol, 1 equiv.) was reduced with zinc borohydride according to general procedure B. The resultant material was purified by flash chromatography on silica (ethyl acetate-petroleum ether, 4 : 1) to give 14b (49 mg, 42%) as a cream solid; mp 92-96 °C (Found: C, 58.35; H, 7.37; N, 10.36. C₁₃H₂₀N₂O₄ requires C, 58.19; H, 7.51; N, 10.44%); v_{max}(CHCl₃)/cm⁻¹ 1525.6, 1641.3, 1739.7, 2958.6, 3438.8; $\delta_{\rm H}$ (500 MHz; CDCl₃; Me₄Si) 0.94 (6 H, m, CH(CH₃)₂), 1.63–1.75 (3 H, m, CH₂CH), 3.76 (3 H, s, CO_2CH_3), 4.60 (2 H, d, J = 2.9 Hz, CH_2OH), 4.76 (1 H, m, NHCH), 6.04 (1 H, dd, J = 2.4, 3.4 Hz, pyrrole 4-H), 6.57 (1 H, dd, J = 2.4, 3.4 Hz, pyrrole 3-H), 6.62 (1 H, d, J = 8.8 Hz, NHCH), 10.51 (1 H, br s, pyrrole NH); $\delta_{\rm C}$ (75 MHz; CDCl₃; Me₄Si) 21.6, 22.8 (CH(CH₃)₂), 24.8 (CH₂CH), 41.0 (CH₂CH), 50.7 (NHCH), 52.4 (CO₂CH₃), 57.3 (CH₂OH), 107.9 (pyrrole 4-C), 110.9 (pyrrole 3-C), 124.6 (pyrrole 2-C), 136.8 (pyrrole 5-C), 161.7 (CONH), 174.5 (CO2); m/z (EI) 268.1418 (M⁺. C₁₃H₂₀N₂O₄ requires 268.1423), 212 (27%), 209 (12), 191 (19), 180 (11), 175 (13), 174 (96), 130 (15), 126 (18), 125 (12), 124 (100), 108 (21), 106 (70), 86 (48) and 78 (31).

Method 2. The pyrrole 13b (35 mg, 0.13 mmol, 1 equiv.), dissolved in dry ether (5 cm³) under an inert atmosphere, was cooled to -78 °C (dry ice-acetone). Lithium borohydride (6 mg, 0.26 mmol, 2 equiv.) was added, and the resultant solution was stirred at -78 °C for 1 h. Water (10 cm³) was carefully added to quench the reaction, and the solution was extracted with ethyl acetate (3 × 10 cm³). The combined organic phases were washed with saturated aqueous brine (10 cm³), dried (MgSO₄), and the solvent was removed by evaporation under reduced pressure. The resultant material was purified by flash chromatography on silica (ethyl acetate-petroleum ether, 4 : 1) to give 14b (23 mg, 66%) as an off-white solid; mp 94–97 °C. Data as above.

N-(5-Hydroxymethyl-1H-pyrrole-2-carbonyl)-L-proline

methyl ester (14c). The pyrrole 13c (120 mg, 0.48 mmol, 1 equiv.) was reduced with zinc borohydride according to general procedure B. The resultant material was purified by flash chromatography on silica (ethyl acetate-acetone, 10:1) to give 14c (29 mg, 24%) as an orange oil; v_{max} (CHCl₃)/cm⁻¹ 1596.9, 1743.5, 3010.7, 3436.9, 3691.5; $\delta_{\rm H}$ (500 MHz; CDCl₃; Me₄Si) 2.03-2.24 (4 H, m, NCH₂CH₂CH₂CH), 3.44 (1 H, br s, CH₂OH), 3.73 (3 H, s, CO₂CH₃), 3.85 (1 H, m, NCH_{2a}CH₂-CH₂CH), 3.95 (1 H, m, NCH_{2b}CH₂CH₂CH), 4.61 (2 H, s, CH₂OH), 4.73 (1H, m, NCH), 6.13 (1 H, s, pyrrole 4-H), 6.60 (1 H, s, pyrrole 3-H), 10.75 (1 H, br s, pyrrole NH); $\delta_{\rm C}$ (75 MHz; CDCl₃; Me₄Si) 25.2, 28.8 (NCH₂CH₂CH₂CH), 48.8 (NCH₂-CH₂CH₂CH), 52.4 (CO₂CH₃), 57.4 (CH₂OH), 60.2 (NCH), 108.2 (pyrrole 4-C), 113.8 (pyrrole 3-C), 124.6 (pyrrole 2-C), 136.9 (pyrrole 5-C), 161.3 (CON), 172.8 (CO₂); m/z (EI) 252.1119 (M⁺. C₁₂H₁₆N₂O₄ requires 252.1110), 252 (20%), 193 (48), 191 (16), 176 (14), 175 (76), 147 (11), 147 (11), 128 (77), 124 (62), 122 (12), 108 (21), 107 (83), 106 (100), 96 (11), 94 (16), 79 (61), 78 (64), 70 (90) and 68 (26).

Ethyl 5-(3-phenylpropionyl)-1*H*-pyrrole-2-carboxylate (15a). A solution of pyrrole ester 11^{12} (2.91 g, 21 mmol, 1 equiv.) in dry 1,2-dichloroethane (35 cm³) was added in a dropwise fashion over 5 min to a stirred suspension of hydrocinnamoyl chloride (7.04 g, 42 mmol, 2 equiv.) and zinc chloride (5.70 g, 42 mmol, 2 equiv.) in dry 1,2-dichloroethane (35 cm³), cooled to 0 °C under an inert atmosphere. The suspension was heated to 50 °C for 1 h, after which the resultant solution was poured

onto ice-water and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (40 cm³), and the combined organic fractions were washed with aqueous saturated sodium hydrogen carbonate (30 cm³), aqueous saturated brine (30 cm³), dried (MgSO₄), and the solvent was removed by evaporation under reduced pressure. The crude material was dissolved in ethyl acetate (50 cm³), washed with 1 M aqueous sodium hydroxide (4 \times 20 cm³) to remove excess hydrocinnamoyl chloride, dried (MgSO₄), and the solvent was removed by evaporation under reduced pressure. The resultant material was purified by flash chromatography on silica (ethyl acetatepetroleum ether, 1 : 4) to give 15a (2.0 g, 35%) as a cream residue; v_{max}(KBr)/cm⁻¹ 1548.7, 1604.7, 1662.5, 1710.7, 2987.5, 3006.8, 3429.2; $\delta_{\rm H}$ (500 MHz; CDCl₃; Me₄Si) 1.36 (3 H, t, J = 7.1Hz, CH_2CH_3), 3.04 (2 H, t, J = 7.3 Hz, $PhCH_2CH_2$), 3.13 (2 H, m, PhCH₂CH₂), 4.35 (2 H, q, J = 7.2 Hz, CH₂CH₃), 6.81 (1 H, dd, J = 2.9, 3.9 Hz, pyrrole H), 6.86 (1 H, dd, J = 2.4, 3.9 Hz, pyrrole H), 7.18-7.30 (5 H, m, ArH), 9.89 (1 H, br s, pyrrole NH); $\delta_{C}(75 \text{ MHz}; \text{ CDCl}_{3}; \text{ Me}_{4}\text{Si})$ 14.2 (CH₂CH₃), 30.2 (PhCH₂CH₂), 40.0 (PhCH₂CH₂), 61.1 (CH₂CH₃), 115.4, 115.5 (pyrrole 3-C and 4-C), 126.2, 128.3, 128.5, 141.8 (ArC), 127.2 (pyrrole 2-C), 133.7 (pyrrole 5-C), 160.3 (CO₂), 190.3 (CH₂CO); m/z (EI) 271.1220 (M⁺. C₁₆H₁₇NO₃ requires 271.1208), 271 (85%), 226 (17), 198 (27), 166 (63), 139 (66), 120 (100), 104 (40) and 91 (48).

Ethyl 5-acetyl-1*H*-pyrrole-2-carboxylate (15b). The pyrrole 11¹² (4.0 g, 29 mmol, 1 equiv.) was treated with acetyl chloride (4.51 g, 57 mmol, 2 equiv.) as described for 15a. Washing with 1 M aqueous sodium hydroxide was not required in this case. The resultant material was purified by flash chromatography on silica (ethyl acetate–petroleum ether, 1 : 2) to give 15b (1.93 g, 37%) as a yellow solid; mp 54–57 °C (lit.,¹⁶ 60–60.5 °C); $\delta_{\rm H}$ (500 MHz; CDCl₃; Me₄Si) 1.36 (3 H, t, *J* = 7.3 Hz, CH₂CH₃), 2.46 (3 H, s, COCH₃), 4.34 (2 H, q, *J* = 7.2 Hz, CH₂CH₃), 6.83 (1 H, t, *J* = 3.2 Hz, pyrrole H), 6.87 (1 H, t, *J* = 3.2 Hz, pyrrole H), 9.82 (1 H, br s, pyrrole NH).

5-(3-Phenylpropionyl)-1*H*-pyrrole-2-carboxylic acid (16a). A stirred solution of the pyrrole ester 15a (801 mg, 2.95 mmol, 1 equiv.) and potassium hydroxide (663 mg, 11.8 mmol, 4 equiv.) in 2 : 1 water-tetrahydrofuran (20 cm³) was heated to 40-50 °C for 2 h. After cooling to rt, the solution was washed with ether (20 cm³), acidified to pH ~1 with concentrated aqueous hydrochloric acid, and extracted with ether $(5 \times 20 \text{ cm}^3)$. The combined ethereal fractions were dried (MgSO₄) and the solvent was removed by evaporation under reduced pressure to give 16a (616 mg, 86%) as a brown solid; mp 181-183 °C; v_{max} (KBr)/cm⁻¹ 1500.5, 1550.7, 1670.2, 1701.1, 2366.5, 2597.9, 3197.8; $\delta_{\rm H}(500$ MHz, acetone- d_6 ,) 3.11 (2 H, t, J = 7.6 Hz, PhCH₂CH₂), 3.32 (2 H, t, J = 7.6 Hz, PhCH₂CH₂), 6.97 (1 H, dd, J = 2.4, 3.9 Hz, pyrrole H), 7.15 (1 H, dd, J = 2.4, 3.9 Hz, pyrrole H), 7.29 (1 H, m, ArH), 7.39 (4 H, m, ArH), 11.23 (1 H, br s, pyrrole NH); $\delta_{\rm C}$ (75 MHz, acetone- d_6) 30.1 (PhCH₂CH₂), 39.9 (PhCH₂CH₂), 115.5, 115.8, 126.1, 128.5, 128.6, 141.6, 127.9 (pyrrole 2-C), 134.8 (pyrrole 5-C), 161.2 (CO₂H), 190.0 (CH₂CO); *m/z* (EI) 243.0900 (M⁺. C₁₄H₁₃NO₃ requires 243.0895), 243 (57%), 143 (60), 120 (100), 113 (63), 104 (72) and 94 (75).

5-Acetyl-1*H***-pyrrole-2-carboxylic acid (16b).** The pyrrole **15b** (1.90 g, 10 mmol, 1 equiv.) was hydrolysed with potassium hydroxide (2.35 g, 42 mmol, 4 equiv.) as described for **15a** to give **16b** (1.50 g, 93%) as a yellow solid; mp 185–187 °C (Found: C, 54.93; H, 4.55; N, 9.07. C₇H₇NO₃ requires C, 54.90; H, 4.61; N, 9.15%); $v_{\text{max}}(\text{KBr})/\text{cm}^{-1}$ 1546.8, 1670.2, 2360.7, 2511.1, 2584.4, 3124.5, 3436.9; $\delta_{\text{H}}(500 \text{ MHz}, \text{acetone-}d_6)$ 2.57 (3 H, s, CH₃CO), 6.98 (1 H, dd, J = 2.4, 3.9 Hz, pyrrole H), 7.11 (1 H, dd, J = 2.4, 3.9 Hz, pyrrole H), 11.20 (1 H, br s, pyrrole NH); $\delta_{\text{C}}(75 \text{ MHz}, \text{ acetone-}d_6)$ 25.5 (CH₃CO), 115.5, 116.2 (pyrrole

3-C and 4-C), 127.9 (pyrrole 2-C), 135.1 (pyrrole 5-C), 161.2 (CO_2H), 188.2 (CH_3CO); m/z (EI) 153.0426 (M^+ . $C_7H_7NO_3$ requires 153.0426), 153 (45%), 138 (21) and 120 (100).

N-[5-(3-Phenylpropionyl)-1H-pyrrole-2-carbonyl]-L-phenylalanine methyl ester (17a). The pyrrole acid 16a (150 mg, 0.62 mmol, 1 equiv.) was coupled with L-phenylalanine methyl ester hydrochloride (146 mg, 0.68 mmol, 1.1 equiv.) according to modified general procedure A. The resultant material was purified by flash chromatography on silica (ethyl acetatepetroleum ether, 2 : 3) to give 17a (175 mg, 70%) as a brown residue (Found: C, 71.37; H, 6.15; N, 7.10. C₂₄H₂₄N₂O₄ requires C, 71.27; H, 5.98; N, 6.93%); v_{max}(KBr)/cm⁻¹ 1529.4, 1548.7, 1668.3, 1741.6, 3008.7, 3425.3; $\delta_{\rm H}(500~{\rm MHz};~{\rm CDCl}_3;~{\rm Me}_4{\rm Si})$ 3.03 (2 H, m, PhCH₂CH₂), 3.14 (2 H, m, PhCH₂CH₂), 3.21 (2 H, m, CH₂Ph), 3.75 (3 H, s, CO₂CH₃), 5.05 (1 H, m, NHCH), 6.46 (2 H, m, pyrrole 3-H and NHCH), 6.78 (1 H, dd, J = 2.4, 3.9 Hz, pyrrole 4-H), 7.10 (2 H, m, ArH), 7.17-7.30 (8 H, m, ArH), 10.00 (1 H, br s, pyrrole NH); $\delta_{\rm C}$ (75 MHz; CDCl₃; Me₄Si) 30.3 (PhCH₂CH₂), 37.9 (CHCH₂Ph), 40.0 (PhCH₂-CH₂), 52.5 (CO₂CH₃), 53.1 (NHCH), 110.4 (pyrrole 3-C), 115.5 (pyrrole 4-C), 126.2, 127.2, 128.3, 128.5, 128.6, 129.3, 135.6, 140.9 (ArC), 129.7 (pyrrole 2-C), 133.3 (pyrrole 5-C), 159.4 (CONH), 171.9 (CO₂Me), 190.0 (CH₂CO); m/z (EI) 404.1745 (M⁺. C₂₄H₂₄N₂O₃ requires 404.1736), 370 (33%), 265 (15), 242 (29), 238 (16), 226 (100), 214 (23), 208 (23), 120 (22) and 91 (81).

N-[5-Acetyl-1*H*-pyrrole-2-carbonyl]-L-phenylalanine methyl ester (17b). The pyrrole acid 16b (200 mg, 1.31 mmol, 1 equiv.) was coupled with L-phenylalanine methyl ester hydrochloride (310 mg, 1.44 mmol, 1.1 equiv.) according to modified general procedure A. The resultant material was purified by flash chromatography on silica (ethyl acetate-petroleum ether, 2:1) to give 17b (375 mg, 91%) as a cream solid. An analytical sample was obtained by diffusion of petroleum ether into a solution of 17b dissolved in ethyl acetate; mp 103-105 °C (Found: C, 65.13; H, 5.84; N, 8.77. C₁₇H₁₈N₂O₄ requires C, 64.96; H, 5.77; N, 8.91%); v_{max}(KBr)/cm⁻¹ 1546.8, 1654.8, 1741.6, 2956.7, 3031.9, 3112.9, 3352.1; $\delta_{\rm H}$ (500 MHz; CDCl₃; Me₄Si) 2.42 (3 H, s, CH₃CO), 3.20 (2 H, m, CH₂Ph), 3.75 (3 H, s, CO_2CH_3), 5.06 (1 H, m, NHCH), 6.52 (1 H, dd, J = 2.9, 3.9 Hz, pyrrole 3-H), 6.67 (1 H, d, J = 7.8 Hz, NHCH), 6.88 (1 H, dd, J = 2.7, 4.2 Hz, pyrrole 4-H), 7.10 (2 H, m, ArH), 7.25 (3 H, m, ArH), 10.11 (1 H, br s, pyrrole NH); δ_{c} (75 MHz; CDCl₃; Me₄Si) 25.8 (CH₃CO), 37.9 (CH₂Ph), 52.5 (CO₂CH₃), 53.2 (NHCH), 110.9 (pyrrole 3-C), 116.3 (pyrrole 4-C), 127.2, 128.6, 129.2, 135.7 (ArC), 130.0 (pyrrole 2-C), 133.6 (pyrrole 5-C), 159.4 (CONH), 172.1 (CO₂), 188.6 (CH₃CO); m/z (EI) 314.1271 (M⁺. C₁₇H₁₈N₂O₄ requires 314.1267), 280 (33%), 162 (24), 152 (73), 136 (100), 120 (32), 118 (15) and 91 (19).

(R,S)-N-[5-(1-Hydroxy-3-phenylpropyl)-1H-pyrrole-2-

carbonyl]-L-phenylalanine methyl ester (18a). The pyrrole 17a (112 mg, 0.28 mmol, 1 equiv.) was reduced with zinc borohydride according to general procedure B. The resultant material was purified by flash chromatography on silica (ethyl acetate–petroleum ether, 1 : 1) to give a mixture of **17a** and **18c** (41 mg); $\delta_{\rm H}$ (18c from mixture; 500 MHz; CDCl₃; Me₄Si) 1.95 (2 H, m, CH₂), 2.63 (4 H, m, 2 × CH₂), 3.18 (2 H, m, CH₂Ph), 3.71 (3 H, s, CO₂CH₃), 5.03 (1 H, m, NHCH), 5.93 (1 H, m, pyrrole 4-H), 6.23 (1 H, d, J = 7.8 Hz, NHCH), 6.45 (1 H, m, pyrrole 3-H), 7.11–7.29 (10 H, m, ArH), 9.35 (1 H, br s, pyrrole NH); *m/z* (EI) 390.1953 (M⁺. C₂₄H₂₆N₂O₃ requires 390.1943), 390 (10%), 356 (18), 228 (38), 212 (100), 208 (18), 124 (59), 120 (13), 107 (15), 91 (55) and 79 (31).

Further elution gave a 1 : 1 mixture of epimers **18a** (24 mg, 21%) as a light yellow oil; v_{max} (KBr)/cm⁻¹ 1521.7, 1602.7, 1641.3, 1741.6, 3012.6, 3030.0, 3436.9; δ_{H} (500 MHz; CDCl₃; Me₄Si) 2.13 (2 H, m, PhCH₂CH₂), 2.75 (2 H, m, PhCH₂CH₂),

3.20 (2 H, m, CHC H_2 Ph), 3.71 and 3.72 (each 3 H, s, CO₂C H_3 , isomers A and B), 4.75 (1 H, m, CHOH), 5.02 (1 H, m, NHCH), 6.02 (1 H, m, pyrrole 4-H), 6.42 (1 H, d, J = 7.3 Hz, NHCH), 6.48 (1 H, m, pyrrole 3-H), 7.11–7.29 (10 H, m, ArH), 10.67 and 10.70 (each 1 H, br s, pyrrole NH, isomers A and B); $\delta_{\rm C}$ (75 MHz; CDCl₃; Me₄Si) 31.8 (PhCH₂CH₂), 38.2 (CHCH₂-Ph), 38.6 and 38.7 (PhCH₂CH₂, isomers A and B), 52.4 (CO₂CH₃), 53.1 (NHCH), 67.1 and 67.1 (CHOH, isomers A and B), 106.4 and 106.5 (pyrrole 4-C, isomers A and B), 110.7 (pyrrole 3-C), 124.0 (pyrrole 2-C), 125.9, 127.2, 128.4, 128.5, 128.6, 129.3, 135.6, 141.6 (ArC), 140.1 (pyrrole 5-C), 161.1 (CONH), 172.0 (CO₂Me); m/z (EI) 388.1800 (M⁺ – H₂O. C₂₄H₂₄N₂O₃ requires 388.1787), 388 (17%), 226 (25), 210 (100), 208 (54), 180 (18) and 91 (23).

(R,S)-N-[5-(1-Hydroxyethyl)-1H-pyrrole-2-carbonyl]-L-

phenylalanine methyl ester (18b). Method 1. A stirred solution of the pyrrole 17b (150 mg, 0.48 mmol, 1 equiv.), dissolved in dry tetrahydrofuran (20 cm³) under an inert atmosphere, was cooled to -78 °C (dry ice-acetone). Lithium borohydride (21 mg, 0.95 mmol, 2 equiv.) was added, and the resultant solution was stirred at -78 °C for 1 h, then warmed to rt and stirred for an additional 1 h. Water (10 cm³) was carefully added to quench the reaction, and the solution was extracted with ethyl acetate $(3 \times 10 \text{ cm}^3)$. The combined organic phases were washed with saturated aqueous brine (10 cm³), dried (MgSO₄) and the solvent was removed by evaporation under reduced pressure. The resultant material was purified by flash chromatography on silica (ethyl acetate-petroleum ether, 4 : 1) to give impure 18b (70 mg, 46%) which could not be purified further; $\delta_{\rm H}$ (from mixture; 500 MHz; CDCl₃; Me₄Si) 1.53 (3 H, m, CH₃CHOH), 3.20 (2 H, m, CH₂Ph), 3.74 (3 H, s, CO₂CH₃), 4.90 (1 H, m, CHOH), 5.03 (1 H, m, NHCH), 6.00 (1 H, s, pyrrole 4-H), 6.48 (1 H, t, J = 2.7 Hz, pyrrole 3-H), 6.68 (1 H, m, NHCH), 7.15 (2 H, d, J = 6.8 Hz, ArH), 7.26 (m, 3 H, m, ArH), 10.71 and 10.73 (each 1 H, br s, pyrrole NH, isomers A and B); m/z (EI) 316.1423 (M⁺. C₁₇H₂₀N₂O₄ requires 316.1423), 298 (11%), 138 (12), 136 (61), 120 (100), 91 (18) and 65 (25).

Method 2. The pyrrole acid **19b** (20 mg, 0.13 mmol, 1 equiv.) was coupled with L-phenylalanine methyl ester hydrochloride (31 mg, 0.14 mmol, 1.1 equiv.) according to general procedure A, except in the workup whereby 0.1 M aqueous hydrochloric acid was used instead of the 3 M aqueous hydrochloric acid. The resultant material was purified by flash chromatography on silica (ethyl acetate-petroleum ether, 4 : 1) to give **18b** (22 mg, 54%) as a colourless oil.

(R,S)-Ethyl 5-(1-hydroxyethyl)-1H-pyrrole-2-carboxylate (19a). A stirred solution of the pyrrole ester 12a¹³ (400 mg, 2.39 mmol, 1 equiv.) in dry tetrahydrofuran (40 cm³) under an argon atmosphere was cooled to -23 °C (dry ice-carbon tetrachloride). Methyllithium (1.50 cm³ of a 1.6 M solution in ether, 2.39 mmol, 1 equiv.) was added over 30 min, and the solution was stirred at -23 °C for 2.5 h. After this, a further 1.50 cm³ of the methyllithium solution was added over 30 min, and the solution was again stirred at -23 °C for 2.5 h. The resultant solution was poured into ether-ice, and once the ice had melted the layers were separated. The organic layer was washed with aqueous saturated brine (25 cm³), water (2 \times 25 cm³), then dried (MgSO₄), and the solvent was removed by evaporation under reduced pressure to give 19a (418 mg, 95%) as a brown oil (Found: C, 58.59; H, 7.22; N, 7.60. C₉H₁₃NO₃ requires C, 59.00; H, 7.15; N, 7.65%); $v_{max}(KBr)/cm^{-1}$ 1693.4, 2983.7, 3020.3, 3446.6; $\delta_{\rm H}$ (500 MHz; CDCl₃; Me₄Si) 1.34 (3 H, t, J = 7.1 Hz, CH_2CH_3), 1.55 (3 H, d, J = 6.8 Hz, CH_3CHOH), 3.08 (1 H, br s, CHOH), 4.29 (2 H, q, J = 7.2 Hz, CH₂CH₃), 4.96 (1 H, q, J = 6.5 Hz, CHOH), 6.05 (1 H, m, pyrrole 4-H), 6.83 (1 H, m, pyrrole 3-H), 9.77 (1 H, br s, pyrrole NH); $\delta_{\rm C}$ (75 MHz; CDCl₃; Me₄Si) 14.4 (CH₂CH₃), 23.2 (CH₃CHOH), 60.4 (CH₂CH₃), 64.0 (CHOH), 106.3 (pyrrole 4-C), 115.9 (pyrrole 3-C), 121.8 (pyrrole 2-C), 141.5 (pyrrole 5-C), 161.9 (CO_2); m/z (EI) 183.0897 (M⁺. C₉H₁₃NO₃ requires 183.0895), 183 (43%), 168 (56), 165 (25), 140 (24), 136 (14), 122 (100), 120 (54), 94 (12), 91 (17) and 65 (28).

(R,S)-5-(1-Hydroxyethyl)-1H-pyrrole-2-carboxylic acid (19b). A stirred solution of the pyrrole ester 19a (575 mg, 3.13 mmol, 1 equiv.), in 1 : 1 tetrahydrofuran-water (10 cm³) under an inert atmosphere, was warmed to 40-50 °C. Sodium hydroxide (377 mg, 9.42 mmol, 3 equiv.) was added, and the progress of the reaction was monitored by thin layer chromatography (ethyl acetate-petroleum ether, 1:1). After 24 h, the solution was cooled to rt, washed with ether (10 cm³), cooled to 0 °C and acidified to pH ~4 by the dropwise addition of 1 M aqueous hydrochloric acid. The resulting solution was extracted with ether $(3 \times 15 \text{ cm}^3)$, the combined ethereal extracts were washed with aqueous saturated brine (15 cm³), dried (MgSO₄), and the solvent was removed by evaporation under reduced pressure to give 19b (85 mg, 17%) as a purple solid. This product was used without further purification; mp 110-115 °C; v_{max}(KBr)/cm⁻¹ 1651.0, 3230.5, 3419.6; $\delta_{\rm H}$ (300 MHz, acetone- d_6) 1.59 (3 H, d, J = 6.3 Hz, CH₃CHOH), 4.43 (1 H, br s, CHOH), 5.02 (1 H, m, CH₃CHOH), 6.20 (1 H, t, J = 3.2 Hz, pyrrole 4-H), 6.87 (1 H, t, J = 3.2 Hz, pyrrole 3-H), 10.47 (1 H, br s, pyrrole NH); $\delta_{\rm C}$ (75 MHz, acetone- d_6) 23.2 (CH₃CHOH), 63.3 (CH₃CHOH), 105.9 (pyrrole 4-C), 115.6 (pyrrole 3-C), 121.8 (pyrrole 5-C), 143.2 (pyrrole 2-C), 161.8 (CO₂H); m/z (EI) 155.0579 (M⁺. C₇H₉NO₃ requires 155.0582), 155 (40%), 140 (56), 137 (46), 122 (100), 119 (64), 112 (14), 91 (69), 69 (15) and 65 (50).

N-(5-Formyl-1H-pyrrole-2-carbonyl)-L-phenylalanyl-L-leucine methyl ester (21). To a stirred suspension of L-phenylalanyl-Lleucine hydrate 20a (200 mg, 0.67 mmol) in dry tetrahydrofuran (10 cm³) at rt was added a 12-fold excess of an ethereal solution of diazomethane in a dropwise fashion over 10 min. After 15 h, the solvent was removed by evaporation under reduced pressure to give the methyl ester 20b (202 mg, quantitative yield) as a light brown oil. This was immediately dissolved in dry dichloromethane (6 cm³) at rt under an inert atmosphere, and to this was added the pyrrole acid 12b¹⁴ (87 mg, 0.63 mmol, 1 equiv.), benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (306 mg, 0.69 mmol, 1.1 equiv.), and N,Ndiisopropylethylamine (89 mg, 0.69 mmol, 1.1 equiv.). The reaction mixture was stirred at rt for 16 h, after which the solution was diluted with ethyl acetate (15 cm³), washed with 1 M aqueous hydrochloric acid (10 cm³), aqueous saturated sodium hydrogen carbonate (10 cm³), aqueous saturated brine (10 cm³), dried (MgSO₄) and the solvent was removed by evaporation under reduced pressure. The resultant material was purified by flash chromatography on silica (ethyl acetate-petroleum ether, 3:1), followed by diffusion of petroleum ether into a solution of the title product dissolved in ethyl acetate, to give 21 (135 mg, 52%) as a tan solid; mp 100–103 °C; v_{max}(KBr)/cm⁻¹ 1558.4, 1635.5, 1674.1, 1743.5, 2958.6, 3286.5; $\delta_{\rm H}$ (500 MHz; CDCl₃; Me₄Si) 0.85 (6 H, m, CH(CH₃)₂), 1.43–1.61 (3 H, m, CH₂CH), 3.13 (2 H, m, CH₂Ph), 3.73 (3 H, s, CO₂CH₃), 4.56 (1 H, m, Leu αH), 5.06 (1 H, q, J = 7.3 Hz, Phe αH), 6.64 (1 H, dd, J = 2.4, 3.9 Hz, pyrrole 3-H), 6.90 (2 H, m, pyrrole 4-H and NHCH), 7.19 (6 H, m, ArH and NHCH), 9.61 (1 H, s, CHO), 10.68 (1 H, br s, pyrrole NH); $\delta_{\rm C}(75$ MHz; CDCl₃; Me₄Si) 22.1, 22.6 (CH(CH₃)₂), 24.8, 41.6 (CH₂CH), 38.8 (CH₂Ph), 51.0 (Leu aCH), 52.5 (CO₂CH₃), 54.7 (Phe aCH), 111.3 (pyrrole 3-C), 119.6 (pyrrole 4-C), 126.9, 128.4, 129.4, 136.4 (ArC), 131.3 (pyrrole 2-C), 134.1 (pyrrole 5-C), 159.7 (PyrCONH), 171.3 (CHCONH), 173.1 (CO2), 180.3 (CHO); m/z (ES) 414.2031 (M⁺ + H. C₂₂H₂₈N₃O₅ requires 414.2029), 414 (100%), 293 (62), 288 (31), 268 (20), 247 (20), 225 (20) and 146 (29).

N-(5-Hydroxymethyl-1*H*-pyrrole-2-carbonyl)-L-phenylalanyl-L-leucine methyl ester (22). The pyrrole 21 (82 mg, 0.20 mmol, 1 equiv.) was reduced with lithium borohydride (9 mg, 0.40 mmol, 2 equiv.) as described for 18b (method 1). The resultant material was purified by flash chromatography on silica (ethyl acetate), followed by diffusion of petroleum ether into a solution of the title product in ethyl acetate, to give 22 (56 mg, 68%) as a cream solid; mp decomp. >85 °C; v_{max} (KBr)/cm⁻¹ 1541.0, 1624.0, 1664.5, 1735.8, 2958.6, 3267.2; $\delta_{\rm H}$ (500 MHz; CDCl₃; Me₄Si) 0.84 (6 H, m, CH(CH₃)₂), 1.44–1.59 (3 H, m, CH₂CH), 3.11 (2 H, m, CH₂Ph), 3.69 (3 H, s, CO₂CH₃), 4.59 (3 H, m, Leu αH and CH₂OH), 5.05 (1 H, q, J = 7.7 Hz, Phe α H), 6.04 (1 H, t, J = 2.9 Hz, pyrrole 4-H), 6.53 (1 H, m, pyrrole 3-H), 7.03 (1 H, br s, NHCH), 7.16 (5 H, m, ArH), 7.25 (1 H, br s, NHCH), 10.41 (1 H, br s, pyrrole NH); $\delta_{\rm C}$ (75 MHz; CDCl₃; Me₄Si) 22.0, 22.6, 24.7, 41.5 (CH₂CH), 38.7 (CH₂Ph), 50.8 (Leu aCH), 52.3 (CO₂CH₃), 54.5 (Phe aCH), 57.5 (CH₂OH), 108.1 (pyrrole 4-C), 111.0 (pyrrole 3-C), 124.9 (pyrrole 2-C), 126.7, 128.4, 129.4, 136.3 (ArC), 136.7 (pyrrole 5-C), 161.2 (PyrCONH), 172.0 (CHCONH), 173.4 (CO₂); m/z (ES) 438.2023 (M⁺ + Na. C₂₂H₂₉N₃NaO₅ requires 438.2005), 438 (100%), 416 (66) and 271 (63).

Acknowledgements

This work was supported by a Royal Society of New Zealand Marsden grant. D. C. M. was personally funded by a Bright Futures Top Achiever Doctoral Scholarship. We also thank Professor John Blunt for help with the difference ¹³C NMR spectroscopy.

References

- 1 A. D. Abell and B. K. Nabbs, Bioorg. Med. Chem., 2001, 9, 621.
- 2 R. M. Stroud, Sci. Amer., 1974, 231, 74.

- 3 A. D. Abell and J. C. Litten, J. Chem. Soc., Chem. Commun., 1998, 919.
- 4 A. D. Abell, B. K. Nabbs and A. R. Battersby, *J. Org. Chem.*, 1998, **63**, 8163.
- 5 A. D. Abell, B. K. Nabbs and A. R. Battersby, J. Am. Chem. Soc., 1998, **120**, 1741.
- 6 A. Kashima, Y. Inoue, S. Sugio, I. Maeda, T. Nose and Y.Shimohigashi, *Eur. J. Biochem.*, 1998, **255**, 12.
- 7 W. Hinz, R. A. Jones and T. Anderson, *Synthesis*, 1986, 620.
 8 R. M. Silverstein, E. E. Ryskiewicz, C. Willard and R. Koehler, *J. Org. Chem.*, 1955, 20, 668.
- 9 W. C. Groutas, M. A. Stanga and M. J. Brubaker, J. Am. Chem. Soc., 1989, 111, 1931.
- 10 J. Laskowski, Jr., M. Tashiro, M. W. Empie, S. J. Park, I. Kato, W. Ardelt and M. Wieczorek, in *Proteinase Inhibitors: Medical and Biological Aspects*, ed. N. Katunuma, H. Umezawa and H. Holzer, Japan Scientific Societies Press, Tokyo, 1983, p 55.
- 11 B. Imperiali and R. H. Abeles, Biochemistry, 1987, 26, 4474.
- 12 D. M. Bailey, R. E. Johnson and N. F. Albertson, *Org. Synth.*, 1971, **51**, 100.
- 13 D. M. Wallace, S. H. Leung, M. O. Senge and K. M. Smith, J. Org. Chem., 1993, 58, 7245.
- 14 M. K. A. Khan, K. J. Morgan and D. P. Morrey, *Tetrahedron*, 1966, 22, 2095.
- 15 Z.-Q. Tian, B. B. Brown, D. P. Mack, C. A. Hutton and P. A. Bartlett, *J. Org. Chem.*, 1997, **62**, 514.
- 16 M. Tani, T. Ariyasu, C. Nishiyama, H. Hagiwara, T. Watanabe, Y. Yokoyama and Y. Murakami, *Chem. Pharm. Bull.*, 1996, 44, 48.
- 17 B. Imperiali and R. H. Abeles, Biochemistry, 1986, 25, 3760.
- 18 E. J. Breaux and M. L. Bender, FEBS Lett., 1975, 56, 81.
- 19 D. Le Nguyen and B. Castro, in *Peptide Chemistry 1987*, ed. T. Shiba and S. Sakakibara, Protein Research Foundation, Osaka, 1988, p 231.
- 20 W. L. F. Armarego and D. D. Perrin, in *Purification of Laboratory Chemicals*, Butterworth-Heinemann, Oxford, 1996.
- 21 R. J. P. Cannell, S. J. Kellam, A. M. Owsianka and J. M. Walker, *Planta Med.*, 1988, 54, 10.
- 22 I. Schechter and A. Berger, *Biochem. Biophys. Res. Commun.*, 1967, 27, 157.